United Therapeutics (UTHR) Competitors

United Therapeutics logo
$353.28 -0.90 (-0.25%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

UTHR vs. ALNY, BIIB, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, HALO, and MDGL

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.

United Therapeutics vs.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$1.83B19.40-$440.24M-$2.62-104.95
United Therapeutics$2.33B6.78$984.80M$22.7715.52

Alnylam Pharmaceuticals presently has a consensus price target of $298.61, indicating a potential upside of 8.60%. United Therapeutics has a consensus price target of $382.08, indicating a potential upside of 8.15%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.72
United Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals received 544 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.19% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.50% of users gave United Therapeutics an outperform vote.

CompanyUnderperformOutperform
Alnylam PharmaceuticalsOutperform Votes
1139
76.19%
Underperform Votes
356
23.81%
United TherapeuticsOutperform Votes
595
62.50%
Underperform Votes
357
37.50%

United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -15.86%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-15.86% N/A -8.38%
United Therapeutics 40.31%19.22%16.15%

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than United Therapeutics. MarketBeat recorded 22 mentions for Alnylam Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.00 beat Alnylam Pharmaceuticals' score of 0.83 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
10 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
United Therapeutics
7 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTHR vs. The Competition

MetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.77B$7.09B$5.79B$9.10B
Dividend YieldN/A2.89%5.28%4.00%
P/E Ratio15.519.6987.3818.40
Price / Sales6.78326.801,003.8277.79
Price / Cash15.9022.6637.4433.55
Price / Book2.775.365.164.80
Net Income$984.80M$125.94M$109.04M$223.10M
7 Day Performance0.28%7.14%2.91%1.44%
1 Month Performance-0.59%4.42%2.65%-0.63%
1 Year Performance64.35%10.55%25.91%23.26%

United Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
4.5074 of 5 stars
$353.28
-0.3%
$382.08
+8.2%
+66.5%$15.77B$2.33B15.511,168Insider Trade
Positive News
ALNY
Alnylam Pharmaceuticals
4.28 of 5 stars
$274.82
+1.3%
$298.61
+8.7%
+61.9%$35.45B$1.83B-104.912,100Upcoming Earnings
BIIB
Biogen
4.7559 of 5 stars
$142.37
-1.1%
$228.80
+60.7%
-39.8%$20.72B$9.84B12.857,570Analyst Revision
NBIX
Neurocrine Biosciences
4.8422 of 5 stars
$150.17
-1.1%
$166.10
+10.6%
+6.7%$15.24B$1.89B40.351,400Analyst Forecast
Insider Trade
INCY
Incyte
4.6926 of 5 stars
$73.72
-0.6%
$75.71
+2.7%
+29.6%$14.19B$4.08B525.992,524Upcoming Earnings
Analyst Upgrade
BMRN
BioMarin Pharmaceutical
4.9706 of 5 stars
$62.50
-1.4%
$94.20
+50.7%
-26.8%$11.93B$2.75B37.493,401Positive News
EXAS
Exact Sciences
4.8301 of 5 stars
$55.34
-1.3%
$72.76
+31.5%
-10.7%$10.28B$2.50B-47.496,600Positive News
EXEL
Exelixis
4.5622 of 5 stars
$32.90
-0.7%
$36.06
+9.6%
+56.8%$9.42B$1.83B21.141,310Upcoming Earnings
RGEN
Repligen
3.8429 of 5 stars
$159.95
-3.8%
$184.73
+15.5%
-17.4%$9.02B$638.76M-435.061,783Positive News
Gap Down
HALO
Halozyme Therapeutics
4.5176 of 5 stars
$56.22
-0.7%
$60.89
+8.3%
+71.1%$7.17B$829.25M18.65390Analyst Forecast
Insider Trade
Positive News
MDGL
Madrigal Pharmaceuticals
3.6985 of 5 stars
$325.26
-2.8%
$351.67
+8.1%
+49.7%$7.09BN/A-12.9790Positive News

Related Companies and Tools


This page (NASDAQ:UTHR) was last updated on 2/6/2025 by MarketBeat.com Staff
From Our Partners